Merck & Co., Inc. logo
Merck & Co., Inc. (MRK)
Compare

MRK Cash Flow Statement

Operating, investing, and financing cash flow analysis

MRK Quarterly Cash Flow Statement (USD)

Quarterly ReportTTM
03/31/2026
12/31/2025
09/30/2025
06/30/2025
03/31/2025
12/31/2024
09/30/2024
06/30/2024
Cash from Operations (CFO)
17.890B3.918B2.857B7.822B3.293B2.500B3.450B9.291B5.637B
8.935B-4.240B2.963B5.785B4.427B5.079B3.743B3.157B5.455B
Depreciation & Amortization
4.594B0.002.466B1.072B1.056B1.099B1.197B1.186B1.132B
605.000M185.000M0.00204.000M216.000M195.000M187.000M195.000M203.000M
Change in Accounts Receivable
47.951B12.210B11.775B12.120B11.846B10.790B10.278B11.381B11.642B
Change in Inventory
Change in Accounts Payable
Change in Working Capital
-4.877B-1.613B-2.319B1.314B-2.259B-3.712B-1.855B2.582B-1.012B
Cash from Investing
-3.775B-991.000M-1.033B-987.000M-764.000M-1.328B-937.000M-783.000M-791.000M
-18.821B-8.779B-10.042B0.000.000.00-2.000M-3.345B0.00
Cash from Financing
Debt Repayment
-981.000M-874.000M-1.252B2.490B-1.345B-1.164B-489.000M-444.000M-251.000M
-8.231B-2.105B-2.018B-2.031B-2.077B-2.050B-1.951B-1.953B-1.986B
14.115B2.927B1.824B6.835B2.529B1.172B2.513B8.508B4.846B
Net Change in Cash
-3.278B-9.292B-3.514B10.187B-659.000M-4.586B-1.370B3.315B5.702B

MRK Annual Cash Flow Statement (USD)

Annual Report
12/31/2025
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
Cash from Operations (CFO)
16.472B21.468B13.006B19.095B14.109B10.253B13.440B10.922B
18.254B17.117B365.000M14.519B13.049B7.067B9.843B6.220B
Depreciation & Amortization
5.838B4.499B3.872B3.909B3.214B3.486B3.310B4.519B
0.00761.000M645.000M541.000M479.000M441.000M417.000M348.000M
Change in Accounts Receivable
11.775B10.278B10.349B9.450B9.230B6.803B6.778B7.071B
Change in Inventory
Change in Accounts Payable
Change in Working Capital
-6.976B-3.667B-2.205B-2.782B-3.839B-4.590B-2.067B-1.553B
Cash from Investing
-4.112B-3.372B-3.863B-4.388B-4.448B-4.429B-3.473B-2.615B
-10.042B-4.093B-12.032B-121.000M-12.907B-6.606B-4.954B-431.000M
Cash from Financing
Debt Repayment
-5.084B-1.306B-1.346B0.00-840.000M-1.281B-4.780B-9.091B
-8.176B-7.840B-7.445B-7.012B-6.610B-6.215B-5.695B-5.172B
12.360B18.096B9.143B14.707B9.661B5.824B9.967B8.307B
Net Change in Cash
1.372B6.409B-5.864B4.606B14.000M-1.769B1.967B1.871B

Values are displayed in USD. Negative numbers shown in red.

Values are displayed in USD. Negative numbers are shown in red.

About Merck & Co., Inc.

Merck & Co., Inc. is a global healthcare leader with operations spanning two core divisions: Pharmaceuticals and Animal Health. The Pharmaceutical segment is dedicated to human health, offering a broad spectrum of medicinal products. These cover crucial therapeutic areas such as oncology, acute hospital care, immunology, neuroscience, virology, cardiovascular conditions, and diabetes. This division also develops vital preventive vaccines for pediatric, adolescent, and adult populations. Meanwhile, the Animal Health segment focuses on the research, development, manufacturing, and marketing of veterinary medications, vaccines, and comprehensive health management solutions for animals. This division further provides innovative digital products designed for animal identification, traceability, and continuous monitoring. Merck's extensive clientele encompasses drug wholesalers, pharmacies, hospitals, and government agencies. It also serves managed healthcare organizations, including health maintenance organizations (HMOs) and pharmacy benefit managers, as well as various other institutional clients. Additionally, the company supplies products to individual physicians and their distributors, veterinarians, and livestock producers. The organization actively engages in strategic collaborations with companies such as AstraZeneca PLC, Bayer AG, Eisai Co., Ltd., Ridgeback Biotherapeutics, and Gilead Sciences, Inc. These partnerships are specifically aimed at the joint development and commercialization of prolonged-acting therapies for HIV. Established in 1891, Merck & Co., Inc. maintains its corporate headquarters in Kenilworth, New Jersey.

Rahway, NJ
73,000 employees
Healthcare / Drug Manufacturers - General
Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
Robert Davis